Paris - Mayer Brown advises SERB Pharmaceuticals, a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, on its agreement to acquire Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer.
The contemplated transaction would involve the merger of SERB with Y-mAbs, including its lead commercial oncology asset, DANYELZA®(naxitamab-gqgk).
Under the terms of the merger agreement, SERB will commence an all-cash tender offer to purchase all outstanding shares of Y-mAbs common stock.
The transaction is expected to close by the fourth quarter of 2025.
Mayer Brown advised SERB Pharmaceuticals on the structuring of the take-private with a team composed of Partner Olivier Parawan, Associates Jean-Philippe Coiffard, Maxime Billaut and Anaëlle Stein in Paris and Partner Remmelt Reigersman and counsel David Goett in Northern California (Palo Alto & San Francisco).